Stanley Krystek

Title: Innovations of Stanley Krystek

Introduction

Stanley Krystek is an accomplished inventor based in Ringoes, NJ (US). He holds three patents that focus on advancements in the treatment of immune diseases. His work has significant implications for the medical field, particularly in addressing autoimmune diseases.

Latest Patents

One of his latest patents involves methods of treating immune diseases by administering antibody polypeptides that antagonize CD40. These antibody polypeptides specifically bind to a novel epitope of human CD40 and do not exhibit CD40 agonist activity. They are particularly useful in treating diseases that involve CD40 activation, such as autoimmune diseases. Additionally, these antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of these antibody polypeptides can be increased by modifying them to be dual-specific reagents that can also bind human serum albumin (HSA). Another patent focuses on nucleic acids encoding these antibody polypeptides, further emphasizing their potential in therapeutic applications.

Career Highlights

Throughout his career, Stanley has worked with notable companies, including Bristol-Myers Squibb Company and Domantis Limited. His experience in these organizations has contributed to his expertise in the field of immunology and antibody development.

Collaborations

Stanley has collaborated with several professionals in his field, including Anish Suri and Steven Sheriff. These collaborations have likely enhanced his research and development efforts.

Conclusion

Stanley Krystek's contributions to the field of immunology through his innovative patents demonstrate his commitment to advancing medical science. His work continues to pave the way for new treatments for immune diseases.